June 6th 2017, 10:06pm
When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.
June 6th 2017, 5:59pm
Many patients with relapsed or refractory multiple myeloma saw clinical remission with CAR T-cell therapy.
June 5th 2017, 9:55pm
Keytruda (pembrolizumab) showed promising signs of clinical activity for patients with advanced gastric or gastroesophageal junction (GEJ), according to updated findings from KEYNOTE-059 study that were presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.
June 5th 2017, 6:48pm
Promising results from a new agent may set the stage for a new standard of care for patients with TRK fusion mutations.
June 4th 2017, 10:21pm
An online tool helped patients to report their symptoms in real time, improving survival, according to findings presented at ASCO 2017.
June 4th 2017, 10:06pm
According to findings presented at ASCO 2017, patients with low-risk advanced colon cancer would benefit from reducing the length of chemotherapy after surgery.
June 4th 2017, 8:19pm
The psychotherapty known as CALM has been shown to ease depression and distress in patients with advanced cancer.
June 4th 2017, 5:59pm
According to phase III findings presented at ASCO 2017, single radiation treatment relieved the symptoms of spinal cord compression in patients with advanced cancer as effectively as a five-day course.
June 3rd 2017, 8:38pm
There are fewer reported incidences of severe long-term side effects after childhood cancer treatment, according to a recent study.
June 2nd 2017, 11:47pm
A recent clinical trial showed that psychological intervention can ease patients' anxiety and fear of recurrence.
June 2nd 2017, 11:07pm
Progression-free survival was improved for postmenopausal women with HER2-negative advanced breast cancer when treated with Kisqali plus letrozole.
March 15th 2017, 9:19pm
Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.
March 15th 2017, 8:20pm
Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.
March 15th 2017, 6:41pm
Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.
March 15th 2017, 4:52pm
PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.
March 15th 2017, 12:37am
Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
March 14th 2017, 10:32pm
The PARP inhibitor niraparib proved to be effective in improving progression-free survival in recurrent ovarian cancer, according to a recent study.
March 13th 2017, 11:53pm
Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against HPV.
March 13th 2017, 10:26pm
Jubilee Brown, M.D., answers some common questions about genetic counseling in patients with ovarian cancer.
March 13th 2017, 9:31pm
Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.
March 13th 2017, 8:59pm
Elizabeth Swisher, M.D., discusses the ARIEL2 study, which proved that rucaparib may be a promising agent for patients with recurrent ovarian cancer.
March 13th 2017, 1:12am
Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.